source
- Bristol Myers reports 52% reduction in progression risk for next-gen multiple myeloma drug in Phase 3 trialBristol Myers Squibb said its next-generation multiple myeloma therapy, positioned as a successor to Pomalyst, lowered the risk of disease progression or death by 52% when added to a standard combi…
- Pfizer partners with China's Innovent Biologics on $10.5 billion deal for 12 early-stage cancer programsPfizer announced a collaboration with Innovent Biologics of China to develop a suite of cancer therapies. The agreement covers up to 12 early-stage antibody‑drug conjugates and multi‑specific anti…